JAK/STAT signaling as a key regulator of ferroptosis: mechanisms and therapeutic potentials in cancer and diseases

被引:0
作者
Dai, Yimeng [1 ]
Cui, Chunguo [2 ]
Jiao, Dan [3 ]
Zhu, Xuewei [4 ]
机构
[1] Jilin Univ, China Japan Union Hosp, Dept Radiol, Changchun, Peoples R China
[2] Jilin Univ, China Japan Union Hosp, Dept Breast Surg, Changchun, Peoples R China
[3] Jilin Univ, China Japan Union Hosp, Dept Ultrasound, Changchun, Peoples R China
[4] Jilin Univ, China Japan Union Hosp, Dept Otolaryngol, Changchun, Peoples R China
关键词
Ferroptosis; JAK/STAT signaling; JAK2; STAT3; STAT1; STAT6; Therapy; INJURY; IRON; AXIS;
D O I
10.1186/s12935-025-03681-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation, playing a critical role in various diseases, including cancer, neurodegeneration, and tissue damage. This study reviews the intricate relationship between ferroptosis and the Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling pathway, highlighting its regulatory functions across multiple biological processes. Dysregulation of the JAK/STAT pathway is implicated in promoting or inhibiting ferroptosis, depending on the context. JAK2 promotes ferroptosis by activating STAT proteins, modulating the expression of key regulators like SLC7A11 and GPX4, and influencing iron homeostasis through pathways such as ferritinophagy and hepcidin regulation. STAT1 activation primarily enhances ferroptosis through the suppression of cystine-glutamate antiporter (System Xc-), leading to glutathione depletion and lipid peroxidation, contributing to cell death in conditions like Sjogren's syndrome and age-related macular degeneration. In contrast, STAT3 plays a protective role by upregulating SLC7A11 and GPX4, which inhibits ferroptosis and promotes cell survival, particularly in cancers such as hepatocellular carcinoma, prostate cancer, and renal cell carcinoma. This study also discusses STAT6's involvement in ferroptosis suppression in diseases like asthma and lung injury by regulating antioxidant defenses. Furthermore, the review explores potential therapeutic strategies targeting the JAK/STAT pathway to manipulate ferroptosis for disease treatment. In cancer therapy, modulating this pathway can enhance the effectiveness of ferroptosis inducers, offering promising avenues to overcome drug resistance. Additionally, the interplay between ferroptosis and JAK/STAT signaling in immune responses, oxidative stress, and lipid metabolism underscores its significance in disease progression and therapeutic intervention. By exploring these mechanisms, this study provides insights into the development of novel treatments targeting ferroptosis through JAK/STAT modulation, with implications for cancer, inflammatory diseases, and neurodegenerative conditions.
引用
收藏
页数:40
相关论文
共 50 条
  • [31] Ferroptosis in Lung Cancer: From Molecular Mechanisms to Prognostic and Therapeutic Opportunities
    Tabnak, Peyman
    HajiEsmailPoor, Zanyar
    Soraneh, Soroush
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [32] A comprehensive overview of recent developments on the mechanisms and pathways of ferroptosis in cancer: the potential implications for therapeutic strategies in ovarian cancer
    Kobayashi, Hiroshi
    Yoshimoto, Chiharu
    Matsubara, Sho
    Shigetomi, Hiroshi
    Imanaka, Shogo
    CANCER DRUG RESISTANCE, 2023, 6 (03) : 547 - 566
  • [33] Ferroptosis: Emerging mechanisms, biological function, and therapeutic potential in cancer and inflammation
    Jin, Xin
    Tang, Jiuren
    Qiu, Xiangyu
    Nie, Xiaoya
    Ou, Shengming
    Wu, Geyan
    Zhang, Rongxin
    Zhu, Jinrong
    CELL DEATH DISCOVERY, 2024, 10 (01)
  • [34] Interplay of ferroptosis, cuproptosis, and PANoptosis in cancer treatment-induced cardiotoxicity: Mechanisms and therapeutic implications
    Yang, Fan
    Zhang, Guoxia
    An, Na
    Dai, Qianqian
    Cho, William
    Shang, Hongcai
    Xing, Yanwei
    SEMINARS IN CANCER BIOLOGY, 2024, 106-107 : 106 - 122
  • [35] JAK-STAT signaling in cancer: From cytokines to non-coding genome
    Pencik, Jan
    Ha Thi Thanh Pham
    Schmoellerl, Johannes
    Javaheri, Tahereh
    Schlederer, Michaela
    Culig, Zoran
    Merkel, Olaf
    Moriggl, Richard
    Grebien, Florian
    Kenner, Lukas
    CYTOKINE, 2016, 87 : 26 - 36
  • [36] Ferroptosis as a Therapeutic Target in Neurodegenerative Diseases: Exploring the Mechanisms and Potential of Treating Alzheimer's Disease and Parkinson's Disease
    Zhong, Hui
    Liu, Hanxiang
    Fu, Qiang
    PROTEIN AND PEPTIDE LETTERS, 2024, 31 (10) : 759 - 772
  • [37] Ferroptosis in thyroid cancer: Potential mechanisms, effective therapeutic targets and predictive biomarker
    Chen, Yuying
    Pan, Gang
    Wu, Fan
    Zhang, Yu
    Li, Yuanhui
    Luo, Dingcun
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 177
  • [38] Neuroepithelial cell transforming 1 as a key regulator in non-small cell lung cancer: unveiling causal links and therapeutic potentials
    Shangguan, Xiaoqing
    Zhang, Xinping
    Chen, Xiwu
    Zhang, Zheng
    Wang, Lei
    TRANSLATIONAL CANCER RESEARCH, 2024, 13 (11) : 6087 - 6104
  • [39] MALAT1: A key regulator in lung cancer pathogenesis and therapeutic targeting
    Bhat, Asif Ahmad
    Afzal, Obaid
    Afzal, Muhammad
    Gupta, Gaurav
    Thapa, Riya
    Ali, Haider
    Almalki, Waleed Hassan
    Kazmi, Imran
    Alzarea, Sami I.
    Saleem, Shakir
    Samuel, Vijaya Paul
    Gubbiyappa, Shiva Kumar
    Subramaniyan, Vetriselvan
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 253
  • [40] YY1: a key regulator inhibits gastric cancer ferroptosis and mediating apatinib-resistance
    Geng, Zi-Han
    Du, Jun-Xian
    Chen, Yue-Da
    Fu, Pei-Yao
    Zhou, Ping-Hong
    Qin, Wen-Zheng
    Luo, Yi-Hong
    CANCER CELL INTERNATIONAL, 2024, 24 (01)